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Abstract
Incidence of esophageal adenocarcinoma (EA) has increased substantially in recent de-
cades. Multiple risk factors have been identified for EA and its precursor, Barrett’s esopha-
gus (BE), such as reflux, European ancestry, male sex, obesity, and tobacco smoking, and
several germline genetic variants were recently associated with disease risk. Using data
from the Barrett’s and Esophageal Adenocarcinoma Consortium (BEACON) genome-wide
association study (GWAS) of 2,515 EA cases, 3,295 BE cases, and 3,207 controls, we ex-
amined single nucleotide polymorphisms (SNPs) that potentially affect the biogenesis or
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biological activity of microRNAs (miRNAs), small non-coding RNAs implicated in post-tran-
scriptional gene regulation, and deregulated in many cancers, including EA. Polymorphisms
in three classes of genes were examined for association with risk of EA or BE: miRNA bio-
genesis genes (157 SNPs, 21 genes); miRNA gene loci (234 SNPs, 210 genes); and
miRNA-targeted mRNAs (177 SNPs, 158 genes). Nominal associations (P<0.05) of 29
SNPs with EA risk, and 25 SNPs with BE risk, were observed. None remained significant
after correction for multiple comparisons (FDR q>0.50), and we did not find evidence for in-
teractions between variants analyzed and two risk factors for EA/BE (smoking and obesity).
This analysis provides the most extensive assessment to date of miRNA-related SNPs in
relation to risk of EA and BE. While common genetic variants within components of the
miRNA biogenesis core pathway appear unlikely to modulate susceptibility to EA or BE, fur-
ther studies may be warranted to examine potential associations between unassessed vari-
ants in miRNA genes and targets with disease risk.
Introduction
Incidence of esophageal adenocarcinoma (EA) in Western countries has risen sharply in recent
decades, while median survival remains less than one year [1]. EA typically arises within a co-
lumnar metaplastic precursor epithelium known as Barrett’s esophagus (BE). Established risk
factors for EA and BE include symptomatic gastroesophageal reflux disease (GERD), European
ancestry, male sex, obesity, and tobacco smoking [2]. Less is known about the role of inherited
genetic variation and its interplay with environmental factors. Candidate-gene-based studies
have associated altered risk of EA or BE with DNA polymorphisms in genes that function in a
wide range of biological pathways (inflammation, detoxification, DNA repair, angiogenesis,
and apoptosis) [3–13], while a recent linkage-based genetic analysis of sibling pairs provided
preliminary evidence for several novel germline mutations [14]. These studies have been limit-
ed by small sample sizes and the need for validation. In the last few years, large genome-wide
association studies of BE and EA identified multiple SNPs significantly associated with disease
risk [15–18], including variants located in three transcription factors, a transcriptional co-acti-
vator, and the major histocompatibility complex locus, none of which were previously impli-
cated by candidate-based studies.
A large body of work has established that microRNAs (miRNAs), small non-coding RNAs
that function in post-transcriptional gene regulation, act as oncogenes or tumor suppressors in
a variety of tissues, and their deregulation can lead to cancer [19,20]. MiRNA gene loci are
transcribed by RNA polymerase II to generate primary (pri-) miRNA transcripts, which are
then cleaved by the nuclear RNAse DROSHA complex to form stem-loop precursor (pre-)
miRNAs. Following nuclear export to the cytoplasm, pre-miRNAs undergo further processing
by the DICER complex to generate mature miRNAs, which typically bind to the 3’ untranslated
region of target messenger RNAs (mRNAs) and mediate translational repression or RNA deg-
radation. MiRNAs have been linked to inflammatory pathways [21,22], which are likely to play
important roles in BE/EA. Changes in miRNA expression have been detected at multiple stages
in the development of EA [23–38], and certain miRNAs may be associated with prognosis
[33,35].
Many studies have reported associations between miRNA-related SNPs and risk of diverse
cancers [39]. These SNPs may reside in a) miRNA biogenesis genes, b) miRNA gene loci, or c)
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miRNA-targeted mRNAs. Functional miRNA-related SNPs may affect global miRNA expres-
sion levels, processing or expression of individual miRNAs, and miRNA target gene specificity.
A previous case-control study of 346 esophageal cancer cases (86% EA) and an equal number
of matched controls reported that seven miRNA-related SNPs from a panel of 41 total SNPs
tested were associated with altered risk of esophageal carcinoma, with the association of one
SNP in the pre-miRNA-423 region remaining statistically significant after correction for multi-
ple comparisons [40]. These SNPs have not been validated in independent study populations
or evaluated for potential associations with BE, and it is currently unknown whether additional
SNPs in the miRNA pathway may modulate disease risk. Using data from a recent genome-
wide association study (GWAS) of 2,515 EA cases, 3,295 BE cases, and 3207 controls [16], we
selected 157 biogenesis pathway SNPs, 234 miRNA SNPs, and 177 mRNA target SNPs and as-
sessed their associations with risks of EA and BE.
Methods
Study population and SNP genotyping
The Barrett’s and Esophageal Adenocarcinoma Genetic Susceptibility Study (BEAGESS) in-
cluded men and women diagnosed with EA or BE, and control participants pooled from 14 in-
dividual studies conducted in Western Europe, Australia, and North America over the past
twenty years. Detailed study population characteristics and genotyping protocols have been
published [16]. Briefly, all EA and BE case participants were confirmed by histologic examina-
tion, and a set of population control individuals was drawn from the included Barrett’s and
Esophageal Adenocarcinoma Consortium (BEACON) studies to serve as a comparison group
for both EA and BE case participants. The current analysis employed a pooled dataset that has
been described previously [41], and included all BEAGESS participants, additional BE and EA
patients from the UK Barrett’s Esophagus Gene Study and the UK Stomach and Oesophageal
Cancer Study (SOCS), respectively [16], and additional controls from a hospital-based case-
control study of melanoma conducted at the MD Anderson Cancer Center (Houston, TX)
[42]. Genotyping of buffy coat or whole blood DNA from all participants was conducted using
the Illumina Omni1M Quad platform, in accordance with standard quality control procedures
[43]. All participants gave written informed consent, and this project was approved by the eth-
ics review board of the Fred Hutchinson Cancer Research Center. We selected all unrelated
participants with missing genotyping call rates< 2%; thus the final study sample included
2,515 EA cases, 3,295 BE cases, and 3,207 controls. Three control participants were excluded
from analyses involving BE cases, because of familial relation to cases.
Selection of miRNA-related SNPs
SNPs selected for this study are located in or near a) miRNA biogenesis genes (+/- 2kb), b)
miRNA gene loci (+/- 25bp), or c) predicted or verified mRNA targets of miRNAs (S1 Fig). We
excluded from consideration SNPs that failed Illumina quality measures or standard quality
control procedures [43]. Specifically, SNPs were excluded if any of the following criteria were
satisfied: i) Illumina GenTrain score< 0.6 or cluster separation< 0.4; ii)>5%missing call rate
over samples; iii) discordant genotype calls in any pair of duplicate study samples; iv) Mendelian
error in either one of the HapMap QC trios or the small number of families identified in the
BEACON data; v) significant departure from Hardy-Weinberg Equilibrium (P<10–4); vi)
minor allele frequency (MAF)< 1%.
After imposing the above filters, we first identified all available Omni1M SNPs (n = 185) lo-
cated within fourteen genes in the miRNA biogenesis core pathway (2kb flanking sequences
for each gene were also included, using gene boundaries defined in hg19/GRChB37): DDX20,
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DGCR8, DICER1, DROSHA, EIF2C1-4, GEMIN4, GW182, PRKRA, RAN, TARBP2, XPO5. Sim-
ilarly, we identified all available Omni1M SNPs (n = 70) located within 1601 human miRNA
precursor sequences (+/- 25bp) deposited in miRBase (version 19). Additional Omni1M SNPs
(n = 160) in pairwise linkage disequilibrium (LD) (r2>0.8) with non-Omni1M dbSNP poly-
morphisms located within the 1601 miRNA precursors (+/-25bp) were also identified, using
1000 Genomes data for the CEU population via the SNP Annotation and Proxy (SNAP) web-
site (http://www.broadinstitute.org/mpg/snap). In the case of multiple possible Omni1M proxy
SNPs, selection was based on maximum r2 coefficient followed by minimum distance (bp).
Within these two categories of SNPs (biogenesis and miRNA gene loci), LD-based pruning
was carried out with pairwise LD data from SNAP, using an r2 threshold of 0.8, to reduce the
number of redundant tests (126/185 biogenesis SNPs and 229/230 miRNA gene SNPs were
retained).
To identify potentially functional SNPs in miRNA-targeted mRNAs, we used a database of
polymorphisms predicted to alter miRNA-mRNA regulation [44]. Two filters were imposed to
limit the set of SNPs to those most likely to be functional. First, we considered miRNA-mRNA
interactions only for miRNAs shown to be expressed in the esophagus at some point in the dis-
ease progression from normal squamous epithelium to BE/EA. Based on the union of several
published reports [32,34–38], 135 expressed miRNAs were identified (S1 Table). Second, after
the previous exclusions, we considered only a subset of miRNA-mRNA interactions (3%)
that were predicted to be most strongly affected by genetic variants in the target mRNA
(ΔS>0.85, where S is the predicted regulation score for a given miRNA:mRNA pairing). LD-
based pruning of these filtered SNPs (n = 175) was performed as described previously (145/175
SNPs were retained).
A literature search was also conducted to identify miRNA-related SNPs shown to be associ-
ated with cancer susceptibility (S2 Table) [39,45–67]. Variants not already captured by our se-
lection process were added if available in the Omni1M dataset, or proxy SNPs in high LD were
substituted where possible, as indicated (S3 Table). The final set of polymorphisms included
157 biogenesis pathway SNPs (21 genes), 234 miRNA SNPs (210 genes), and 177 target mRNA
SNPs (158 genes). Minor and major alleles were reported throughout using the ‘plus’ strand
designation.
Statistical analysis
Unconditional multivariate logistic regression was used to compute odds ratios for risk of EA
or BE associated with a given SNP variant, using an additive model (per-allele), while adjusting
for age, sex, and the first four principal components (PCs) derived from principal components
analysis (PCA) to account for population stratification by ancestry [41]. Inclusion of the first
four PCs was empirical, as described previously in the parent GWAS report [16], and based on
assessment of i) the percentage of variance accounted for (S2 Fig) and ii) the observed separa-
tion of study participants according to pairwise comparisons of individual principal compo-
nents (S3 Fig). To correct for multiple comparisons when assessing statistical significance,
we used the Bonferroni or Benjamini-Hochberg false-discovery rate (FDR) methods [68,69].
The threshold for Bonferroni significance was α = 0.05/568 = 8.80x10-5. Stratified analyses by
body mass index (BMI, kg/m2) and history of cigarette smoking were also conducted, and evi-
dence for interaction was assessed by including a product term in the logistic regression model.
Smoking history and BMI were defined categorically in stratified analyses (smoking: ever/
never, or pack-years: 0,>0 &<15, 15–29, 30–44, 45+; BMI:<25, 25–29, 30–34, 35+), and con-
tinuously (pack-years, BMI) to test for interaction. Statistical analyses were conducted using
STATA/SE version 13.1 (College Station, TX).
MiRNA-Related SNPs and Risk of EA and BE
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Results
Characteristics of study participants
The distributions of demographic characteristics among controls, EA cases, and BE cases are
shown in Table 1. EA cases were somewhat older (mean age: 65.0 years) and more frequently
male (87%) relative to controls (mean age: 58.4 years, 73% male) and BE cases (mean age: 63.0
years, 76% male). Among participants with non-missing data for BMI and smoking history,
the percentage reporting ever having smoked cigarettes was higher among EA (75%) and BE
(66%) cases than among controls (59%). Heavy smoking (45+ pack years) was more prevalent
among EA cases (21%) than among controls (14%) or BE cases (14%), while obesity (BMI 30+)
was more prevalent among EA (30%) and BE (37%) cases than among controls (20%).
Associations of miRNA-related SNPs and risk of EA or BE
Of the 157 biogenesis pathway SNPs, 234 miRNA SNPs, and 177 mRNA target SNPs evaluated
in this study (S3 Table), 29 were nominally associated (P<0.05) with risk of EA (Table 2 and
S4 Fig), and 25 with risk of BE (Table 3). Three SNPs satisfied P<0.05 in both analyses (EA
and BE): RDH8 rs1644730 T>A,miR-3117 rs7526812 T>C, andmiR-4467 rs12534337 G>A.
For each of these SNPs, the risk estimates for EA and BE were similar and in the same
Table 1. Characteristics of controls, EA cases, and BE cases.
Controls EA BE
(n = 3207) (n = 2515) (n = 3295)
n % n % n %
Agea
<50 726 22.6 189 7.6 449 13.7
50–59 885 27.6 547 21.9 780 23.7
60–69 963 30.0 884 35.4 1011 30.7
70+ 633 19.7 875 35.1 1048 31.9
Sex
Female 880 27.4 320 12.7 806 24.5
Male 2327 72.6 2195 87.3 2489 75.5
BMIa
<25 786 36.3 245 24.6 425 20.7
25–29.99 944 43.6 455 45.7 882 42.9
30–34.99 307 14.2 201 20.2 521 25.3
35+ 130 6.0 95 9.5 230 11.2
Smoking statusa
no 889 40.9 348 24.7 798 33.7
yes 1284 59.1 1062 75.3 1570 66.3
Smoking (p-y)a,b
none 889 41.3 348 32.8 798 44.5
<15 358 16.6 156 14.7 320 17.9
15–29 326 15.1 160 15.1 232 12.9
30–44 273 12.7 173 16.3 198 11.0
45+ 309 14.3 225 21.2 244 13.6
aNumbers do not add to total subjects due to missing data
bpack-years
doi:10.1371/journal.pone.0128617.t001
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directions (OR 0.88 vs 0.93, 1.14 vs 1.11, 1.28 vs 1.25, respectively) (S4 Table). After correction
for multiple comparisons (n = 568 total SNPs), using the Bonferroni or false discovery rate
method, none of the observed associations remained statistically significant (FDR q>0.50).
Table 2. MiRNA-related SNPs and risk of EA.#
Biogenesis pathway
Controls EA cases
SNP Gene Alleles† N MAF‡ N MAF‡ OR* 95% CI P q
1 kgp1460594 XPO5 A/G 3207 0.075 2495 0.091 1.21 (1.05–1.40) 0.0074 0.54
2 rs7702984 DROSHA G/A 3206 0.012 2494 0.009 0.63 (0.43–0.94) 0.0227 0.70
3 rs4351606 EIF2C3 A/G 3205 0.056 2493 0.047 0.82 (0.69–0.98) 0.0327 0.84
miRNA genes
Controls EA cases
SNP Gene Alleles† N MAF‡ N MAF‡ OR* 95% CI P q
1 rs17880825 miR-4725 C/T 3206 0.020 2494 0.028 1.46 (1.13–1.89) 0.0037 0.54
2 rs1709696 miR-3612 A/C 3205 0.227 2493 0.208 0.88 (0.80–0.97) 0.0086 0.54
3 rs1378940 miR-4513 C/A 3206 0.343 2495 0.314 0.89 (0.82–0.97) 0.0091 0.54
4 rs12534337 miR-4467 A/G 3205 0.042 2495 0.053 1.28 (1.06–1.55) 0.0095 0.54
5 rs12564376 miR-4421 A/G 3207 0.039 2495 0.030 0.75 (0.60–0.94) 0.0108 0.55
6 rs7526812 miR-3117 C/T 3207 0.151 2495 0.165 1.14 (1.02–1.27) 0.0195 0.70
7 rs7210250 miR-4521 G/A 3206 0.019 2493 0.015 0.70 (0.51–0.94) 0.0201 0.70
8 rs7342570 miR-487a T/C 3206 0.197 2495 0.213 1.12 (1.02–1.24) 0.0204 0.70
9 rs3787547 miR-4756 A/G 3205 0.435 2495 0.415 0.91 (0.84–0.99) 0.0236 0.70
10 rs9842591 miR-5186 A/C 3207 0.459 2494 0.475 1.09 (1.01–1.18) 0.0280 0.78
11 rs12232826 miR-638 T/G 3207 0.047 2495 0.035 0.81 (0.66–0.99) 0.0356 0.86
12 rs12461701 miR-3188 A/G 3206 0.278 2495 0.259 0.91 (0.83–0.99) 0.0366 0.86
13 rs10899620 miR-5579 C/T 3199 0.194 2490 0.185 0.90 (0.82–1.00) 0.0435 0.87
mRNA targets
Controls EA cases
SNP Gene Alleles† N MAF‡ N MAF‡ OR* 95% CI P q
1 rs1644730 RDH8 A/T 3202 0.472 2495 0.441 0.88 (0.81–0.95) 0.0011 0.54
2 rs1045968 PRRT2 A/C 3206 0.141 2494 0.160 1.17 (1.05–1.31) 0.0046 0.54
3 rs1050629 MLF2 A/G 3206 0.025 2495 0.033 1.40 (1.10–1.78) 0.0055 0.54
4 rs2075993 E2F2 T/C 3206 0.499 2494 0.480 0.90 (0.83–0.97) 0.0072 0.54
5 rs9804386 MORN4 C/T 3207 0.200 2495 0.221 1.14 (1.03–1.25) 0.0088 0.54
6 rs1799782 XRCC1 T/C 3207 0.066 2495 0.053 0.82 (0.69–0.97) 0.0207 0.70
7 rs1367 SCUBE2 G/A 3207 0.075 2494 0.063 0.83 (0.71–0.97) 0.0225 0.70
8 rs11169571 ATF1 C/T 3206 0.391 2494 0.424 1.10 (1.01–1.19) 0.0237 0.70
9 rs2521795 GDE1 A/G 3206 0.151 2495 0.162 1.13 (1.01–1.26) 0.0289 0.78
10 rs3209160 ZDHHC21 C/G 3201 0.137 2490 0.153 1.13 (1.01–1.26) 0.0384 0.87
11 rs3660 KRT81 G/C 3198 0.470 2490 0.485 1.09 (1.00–1.17) 0.0414 0.87
12 rs3174352 ASPN A/G 3206 0.504 2493 0.482 0.92 (0.86–1.00) 0.0493 0.87
13 rs11550670 STXBP6 T/C 3204 0.204 2491 0.220 1.10 (1.00–1.22) 0.0495 0.87
#nominal P<0.05
†Minor/major alleles
‡Minor allele frequency
*OR adjusted for age, sex, PC1-PC4, using additive model (per-allele)
doi:10.1371/journal.pone.0128617.t002
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Stratified analyses by smoking history and BMI
Stratified analyses were conducted to determine whether or not selected top candidates listed
in Tables 2 & 3 (P<7.5x10-3) exhibited disease-risk associations that varied by pack-years of
smoking history or by BMI (S5 and S6 Tables). Assessment of all 568 variants revealed multi-
ple nominally-significant interactions with smoking history or BMI, but none remained signifi-
cant after correction for multiple comparisons (FDR q>0.05). One variant (rs595055 T>C) in
the biogenesis gene EIF2C1 exhibited a borderline-significant interaction (P = 0.0001,
Table 3. MiRNA-related SNPs and risk of BE.#
Biogenesis pathway
Controls BE cases
SNP Gene Alleles† N MAF‡ N MAF‡ OR* 95% CI P q
1 rs8192593 TARBP2 T/C 3201 0.040 3286 0.034 0.77 (0.63–0.93) 0.0063 0.89
2 rs595055 EIF2C1 C/T 3202 0.142 3288 0.125 0.88 (0.79–0.97) 0.0136 0.89
3 rs2944760 EIF2C2 C/A 3198 0.199 3287 0.186 0.90 (0.82–0.98) 0.0198 0.89
4 rs12741800 LIN28 A/G 3198 0.458 3276 0.442 0.92 (0.86–0.99) 0.0231 0.89
5 rs11247946 LIN28 G/A 3204 0.345 3288 0.327 0.92 (0.85–0.99) 0.0295 0.89
6 rs538779 DDX20 A/G 3204 0.217 3288 0.202 0.91 (0.83–0.99) 0.0323 0.89
7 rs6598964 LIN28 T/C 3204 0.368 3288 0.348 0.93 (0.86–1.00) 0.0391 0.89
8 rs12044203 EIF2C4 A/G 3194 0.021 3284 0.014 0.75 (0.57–0.99) 0.0420 0.89
miRNA genes
Controls BE cases
SNP Gene Alleles† N MAF‡ N MAF‡ OR* 95% CI P q
1 rs3785722 miR-1269b A/G 3203 0.449 3288 0.422 0.89 (0.83–0.96) 0.0021 0.89
2 rs10906086 miR-548ak C/A 3203 0.469 3286 0.490 1.10 (1.03–1.19) 0.007 0.89
3 rs7000768 miR-3686 G/A 3204 0.304 3288 0.325 1.11 (1.02–1.19) 0.0104 0.89
4 rs12534337 miR-4467 A/G 3202 0.042 3287 0.052 1.25 (1.05–1.48) 0.0106 0.89
5 rs10862193 miR-617 G/A 3200 0.428 3281 0.409 0.92 (0.86–0.99) 0.0206 0.89
6 rs4369899 miR-4431 C/T 3204 0.338 3285 0.316 0.91 (0.85–0.99) 0.0214 0.89
7 rs2114358 miR-1206 G/A 3204 0.391 3288 0.408 1.09 (1.01–1.17) 0.0273 0.89
8 rs17252270 miR-548x-2 T/C 3203 0.140 3286 0.150 1.12 (1.01–1.24) 0.0283 0.89
9 rs7211449 miR-548h-3 A/C 3203 0.211 3288 0.196 0.91 (0.83–0.99) 0.0347 0.89
10 rs10840491 miR-4686 T/C 3203 0.139 3288 0.125 0.90 (0.81–1.00) 0.0447 0.89
11 rs7526812 miR-3117 C/T 3204 0.151 3287 0.159 1.11 (1.00–1.22) 0.0456 0.89
mRNA targets
Controls BE cases
SNP Gene Alleles† N MAF‡ N MAF‡ OR* 95% CI P q
1 rs1043681 THAP3 C/T 3204 0.316 3288 0.301 0.90 (0.83–0.97) 0.0064 0.89
2 rs7248876 ZNF181 G/A 3200 0.333 3286 0.357 1.10 (1.02–1.18) 0.0139 0.89
3 rs1043420 CAPN5 C/T 3203 0.222 3288 0.236 1.10 (1.01–1.20) 0.0247 0.89
4 rs13043447 CABLES2 T/C 3204 0.080 3287 0.071 0.86 (0.76–0.99) 0.0324 0.89
5 rs1043641 ACBD3 A/G 3204 0.172 3288 0.158 0.90 (0.82–0.99) 0.0331 0.89
6 rs1644730 RDH8 A/T 3199 0.473 3285 0.453 0.93 (0.86–1.00) 0.0384 0.89
#nominal P<0.05
†Minor/major alleles
‡Minor allele frequency
*OR adjusted for sex, PC1-PC4, using additive model (per-allele)
doi:10.1371/journal.pone.0128617.t003
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q = 0.057) with BMI in relation to risk of BE, with elevated disease risk seen only among
obese individuals.
Discussion
Using genotyping data from a recent consortium-based GWAS, we evaluated the association
of 568 miRNA-related SNPs with risks of EA and BE. In total, 29 SNPs were found to be
nominally associated (P<0.05) with risk of EA, and 25 with risk of BE, with three shared vari-
ants identified between these analyses. None remained significant after correction for multi-
ple comparisons.
Aberrant expression of miRNAs has been reported in many cancers, and several studies
have described miRNA expression changes at specific stages in the development of EA, which
may be associated with progression or prognosis [24,29,31,33,35,36]. Inherited genetic varia-
tion in the miRNA pathway has been linked to altered susceptibility to a variety of cancers, but
few studies have focused on esophageal cancer, and in particular, EA (as opposed to esophageal
squamous cell carcinoma, ESCC) [39,40,70,71]. The largest previous study included 386 esoph-
ageal cancer cases (86% EA, n = 296) [40], and identified seven SNPs significantly associated
with cancer risk, five of which were associated specifically with EA. Of those, a single SNP in
the pre-miR-423 region remained significant after adjustment for multiple comparisons. This
variant failed to validate in our own present study of>2,500 EA cases and>3,200 controls.
Since BE is an established risk factor for, and the only known precursor of, EA, it was of in-
terest to compare the list of SNPs nominally associated with risk of each condition. For each of
the three variants reaching P<0.05 in both analyses (RDH8 rs1644730 T>A,miR-3117
rs7526812 T>C, andmiR-4467 rs12534337 G>A), the direction and magnitude of the OR was
very similar for BE and EA (S4 Table), raising the possibility that the association with risk of
BE might account for the association with risk of EA. However, given our use of a single control
group for comparison to both the EA and BE case groups, cautious interpretation is required,
since some shared associations could be expected by chance alone. When EA and BE cases
were combined into a single case group and compared to the same set of controls, all three of
these variants were highly-ranked among the set of 31 nominally significant SNPs (S7 Table),
and two of the three (rs7526812 T>C, rs12534337 G>A) had smaller P values than observed
in the individual analyses, without reaching Bonferroni or FDR significance thresholds.
rs1644730 T>A is located within a predicted miR-630 binding site in the 3’UTR of all-
trans-retinol dehydrogenase 8 (RDH8), which encodes a short-chain dehydrogenase/reductase
enzyme involved in rhodopsin regeneration in the vision pathway. Of interest, the enzymatic
activity of RDH8 has also been linked to estrogen biosynthesis [72]. Given the significantly
higher incidence of BE/EA among males versus females, a potential protective effect of estro-
gens has been proposed, and some evidence exists for reduced disease risk associated with hor-
mone replacement therapy [73]. An intriguing hypothesis relates to whether the suggested
inverse association observed in this study for rs1644730 T>Amay reflect impaired miRNA-
mediated repression of RDH8 and consequent elevations in estrogen synthesis. In exploratory
analyses stratified by sex, the inverse association of this variant with risk of EA appeared stron-
ger among males (OR = 0.86, p = 0.00057, q = 0.23) relative to the overall study sample
(OR = 0.88, p = 0.0011, q = 0.54), and was not evident among the limited pool (n = 1200) of fe-
male participants (OR = 0.97, p = 0.79). rs12534337 G>A is located in the miR-4467 precursor,
identified by deep sequencing of the small RNA transcriptome of normal and malignant B
cells, and paired normal and tumor breast tissue (68, 69). Expression of miR-4467 has not been
assessed in the esophagus, and no studies have examined functional effects of this miRNA. The
proto-oncogene JUNBmRNA is predicted by the TargetScan algorithm to be one of 23
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conserved targets of miR-4467, but experimental validation has not been reported. Any influ-
ence of this SNP on the biogenesis of miR-4467 remains to be determined. rs7526812 T>C is
located ~15kb downstream from, and is in strong linkage disequilibrium (r2 = 1.0) with, a vari-
ant in the miR-3117 gene locus (rs12402181). rs7526812 T>C is also a missense polymorphism
situated within an exon of the SGIP gene, which has been genetically linked to fat mass [74].
Five of the seven SNPs reported to be associated with risk of esophageal cancer (EA/ESCC)
by Ye et al. [40] were included in our analysis of genotyped SNPs from the BEACON GWAS,
including their single SNP (pre-miR-423 rs6505162) reported as significant after correction for
multiple comparisons. Three of these five SNPs had been associated with EA (miR-423
rs6505162,miR-196a-2 rs11614913, and RAN rs14035), while two reached borderline signifi-
cance (XPO5 rs11077 and pri-miR-219-1 rs213210). In our study, none of these five SNPs were
(nominally) associated (P<0.05) with either EA or BE (S8 Table), and nearly all ORs were very
close to 1. Ye et al. evaluated three genetic models (additive, recessive, dominant) and reported
the best-fitting model in their analysis, in contrast to our approach of assessing exclusively the
additive model. Re-analysis of these five SNPs using the alternative models resulted in one
polymorphism reaching borderline significance (pri-miR-219-1 rs213210 T>C, dominant
model, EA OR 1.17, 95% CI 1.01–1.47, P = 0.06), in the same direction as the previously pub-
lished results (OR 1.61, P = 0.058). Ye et al. did not evaluate any of the nominally-associated
variants identified in our analysis. Multiple factors could account for discrepancies between
studies. First, many apparent signals in association studies may be false positives, and replica-
tion in large, independent populations is critical (our EA analysis included more than eight
times as many cases as the previous study). Second, different approaches were taken in adjust-
ment for covariates. While both studies included only individuals of European ancestry, we
also adjusted for population stratification via inclusion of several PCs derived from principal
components analysis, but chose not to adjust for smoking status.
Strengths of our study included the use of pooled data from the BEACON GWAS, which
provided the largest sample size to date in the evaluation of miRNA-related SNPs and risks of
EA and BE. Inclusion of both BE and EA cases allowed for a comparison of the genetic varia-
tion associated with risk of a neoplastic precursor lesion and the cancer that arises from it. The
availability of covariate data for smoking history and BMI further enabled us to evaluate gene-
environment interactions for two established risk factors for these conditions. Our assessment
of 568 polymorphisms significantly expands upon past efforts to examine genetic variation in
miRNA pathways in relation to risk of Barrett’s esophagus and esophageal adenocarcinoma. In
particular, our inclusion of>120 SNPs within 14 genes implicated in miRNA biogenesis al-
lowed for broad coverage of this canonical core pathway, activity of which underlies the global
expression of miRNAs.
This study also had certain limitations. First, while the EA/BE GWAS employed in our anal-
yses represents the largest study of its kind currently available, it remains plausible that among
the variants examined, some true associations of small magnitude were missed due to power
constraints, especially those present exclusively in population sub-groups. Missing data for
smoking/obesity in a fraction of participants further restricted the size of our study sample for
stratified analyses and assessment of effect modification. Second, our examination of genetic
variation within miRNA gene loci and miRNA-targeted mRNAs was not comprehensive. Of
the ~1600 miRNAs deposited in miRBase, only ~200 were represented in our analysis. We
used stringent rather than exhaustive inclusion criteria for selecting miRNA-targeted mRNAs
for analysis, and prioritized targets for which expression of cognate miRNAs has been reported
in esophageal tissue. While this category of variants could have been vastly expanded based on
bioinformatic predictions, the majority of such predicted miRNA:mRNA interactions are not
validated, and are of unknown biological significance.
MiRNA-Related SNPs and Risk of EA and BE
PLOSONE | DOI:10.1371/journal.pone.0128617 June 3, 2015 9 / 14
In sum, our results do not provide evidence for an association between common genetic var-
iation in components of the miRNA biogenesis core pathway and altered risk of EA or BE. Ad-
ditional studies may be justified to examine potential associations between unassessed
germline variants in miRNA gene loci and miRNA target genes and risk of these conditions.
Validation in independent study populations, coupled with functional evaluation of the biolog-
ical effects of specific SNPs, would be needed to substantiate any polymorphisms as causal risk
factors for BE or EA.
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